US Patent
US7417042 — Compounds for enzyme inhibition
Composition of Matter · Assigned to Proteolix Inc · Expires 2026-07-20 · 0y remaining
Vulnerability score
22/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects peptide-based compounds that inhibit specific activities of certain enzymes, including the chymotrypsin-like activity of the 20S proteasome.
USPTO Abstract
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Drugs covered by this patent
- Kyprolis (carfilzomib) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.